General
Preferred name
ZONISAMIDE
Synonyms
Ad 810 ()
Zonisamide sodium ()
Zonisamide (sodium) ()
AD 810 sodium ()
CI 912 sodium ()
CI 912 ()
Zonegran,CI-912,AD 810 ()
N03AX15 ()
Zonisade ()
CI-912 ()
Excegran ()
Zonegran ()
PD-110843 ()
AD-810 ()
Zonisamide-13C2,15N ()
P&D ID
PD002942
CAS
68291-97-4
1188265-58-8
Tags
natural product
drug
available
Approved by
PMDA
EMA
FDA
First approval
2000
Drug Status
investigational
approved
Drug indication
Anticonvulsant
Epilepsy
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Zonisamide is a sulfonamide and therefore unrelated to other seizure medications. The mechanism is not know but it may block sodium and calcium channels. Blocking of these channels may prevent neuronal hypersynchronization. Sonisamide has also been found to potentiate dopaminergic and serotonergic neurotransmission but does not appear to potentiate syanptic activity by GABA (gamma amino butyric acid).
ABSORPTION The absorption is rapid with a time to peak concentration of 2.8-3.9 hours. Food has not effect on bioavailability.
DESCRIPTION Zonisamide is a sulfonamide anticonvulsant. (GtoPdb)
DESCRIPTION Dual CaV1.x and CaV2.x blocker (Tocris Bioactive Compound Library)
DESCRIPTION Blocks voltage-sensitive Na+ and Ca2+ channels (T-type) (Tocriscreen Plus)
DESCRIPTION Antiepileptic; effective in various animal epilepsy models and in humans with both partial and generalized epileptic seizures (LOPAC library)
DESCRIPTION Blocks voltage-sensitive Na+ and Ca2+ channels (T-type) (Tocriscreen Total)
Cell lines
0
Organisms
1
Compound Sets
31
Cayman Chemical Bioactives
24183
28807
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL750
ChEMBL Drugs
CHEMBL750
Drug Repurposing Hub
DrugBank
DB00909
DrugBank Approved Drugs
DB00909
DrugCentral
2872
DrugCentral Approved Drugs
2872
DrugMAP
DM0DTF7
DrugMAP Approved Drugs
DM0DTF7
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101701
Guide to Pharmacology
7047
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL750
MedChem Express Bioactive Compound Library
HY-B0124
NCATS Inxight Approved Drugs
459384H98V
NIH Clinical Collections (NCC)
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Zonisamide
TargetMol Bioactive Compound Library
T0267
The Spectrum Collection
Tocris Bioactive Compound Library
2625
Tocriscreen Plus
2625
Tocriscreen Total
ZINC Tool Compounds
ZINC000000004321
External IDs
53
Properties
(calculated by RDKit )
Molecular Weight
212.03
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
2
cLogP
0.62
TPSA
86.19
Fraction CSP3
0.12
Chiral centers
0.0
Largest ring
6.0
QED
0.79
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Ion Channels
Target
Calcium Channel
Sodium Channel
Sodium channel alpha subunit
Carbonic Anhydrase
CA1, CA10, CA11, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9, CACNA1G, CACNA1H, CACNA1I, MAOA, MAOB, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A
Pathway
Membrane Transporter/Ion Channel
Neuronal Signaling
Metabolism
Apoptosis
Metabolic Enzyme/Protease
MOA
voltage-gated sodium channel blocker
voltage-gated calcium channel blocker
sodium channel blocker, T-type calcium channel blocker
Primary Target
Other Channel Modulators
Indication
seizures, epilepsy
Therapeutic Class
Analgesics
Source data